Navigation Links
Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
Date:11/15/2010

Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Clinical Trials & Medical Discoveries Click to view news release full screen  

Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data

 

TSX Exchange Symbol: RVX CHICAGO and CALGARY, Nov. 15 /PRNewswire-FirstCall/ - Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Wednesday, November 17, 2010 at 1:30 pm Central/12:30 pm Mountain time. The purpose of the teleconference is to discuss the top line results of the Company's Phase 2 clinical trial (ASSERT) for RVX-208, an oral small molecule in development to treat atherosclerosis and cardiovascular disease.

The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix101117.html

The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event. About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit href="http://www.resverlogix.com/">www.resverlogix.com.

This media alert may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this media alert are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast
2. Resverlogix Board of Directors Update
3. Resverlogix Issues a Management Statement
4. Resverlogix Eliminates Sixty Percent of Remaining Debt
5. Resverlogix Announces Closing of Debt Redemption
6. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
7. Resverlogix Board of Directors Update
8. Resverlogix Provides Quarterly Update
9. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
10. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
11. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... closer look at four equities in the Biotech industry: ... EYEG), Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus ... March 21 st , 2017, Credit Suisse upgraded its rating ... stocks by downloading their free report at: ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... human tissue regeneration from small lab samples to full-size tissues, bones, even whole ... establish a vascular system that delivers blood deep into the developing tissue. ...
(Date:3/22/2017)... 2017 Good Start Genetics, a leading family ... 130 million covered lives mark through its most recent ... Texas . With newly signed contracts nationally and ... strong payor acceptance based on the quality of its ... counseling, its industry-leading customer care and support and its ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
Breaking Biology Technology:
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
Breaking Biology News(10 mins):